Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index; 9 of the 13 sources its claims cite were checked for support.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. METHODS: In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. RESULTS: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. CONCLUSIONS: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
CoChat Summary
TL;DR
In a phase 2/3 multinational trial, two 30-μg doses of BNT162b2 given 21 days apart were 95% effective against laboratory-confirmed Covid-19 in participants 16 years of age or older. The vaccine’s safety profile was characterized mainly by short-term, mild-to-moderate local and systemic reactions, with serious adverse events similar between vaccine and placebo groups.
Key findings
- Among 43,548 randomized participants, 43,448 received injections: 21,720 BNT162b2 and 21,728 placebo. In the efficacy population without prior infection, there were 8 Covid-19 cases in vaccine recipients vs. 162 in placebo recipients, corresponding to 95.0% vaccine efficacy (95% CI, 90.3 to 97.6).
- Among participants with or without evidence of prior SARS-CoV-2 infection, 9 Covid-19 cases occurred in vaccine recipients vs. 169 in placebo recipients, for 94.6% efficacy (95% CI, 89.9 to 97.3).
- Of 10 severe Covid-19 cases with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. Between the first and second doses, vaccine efficacy was 52% (95% CI, 29.5 to 68.4).
- Reactogenicity was mostly mild-to-moderate; common events included injection-site pain, fatigue, and headache. Serious adverse events occurred in 0.6% of vaccine recipients and 0.5% of placebo recipients.
Methods
- Ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial; participants 16 years of age or older were randomly assigned 1:1 to receive two doses, 21 days apart, of 30 μg BNT162b2 or saline placebo.
- Primary end points were efficacy against laboratory-confirmed Covid-19 and safety. Efficacy was estimated as 100×(1−IRR), with a Bayesian beta-binomial model; safety analyses were descriptive.
- The main safety subset included 37,706 participants with a median of at least 2 months of safety data after the second dose; the reactogenicity subset included 8,183 participants.
Limitations
- The paper states that with approximately 19,000 participants per group and a median follow-up of 2 months after the second dose, the trial is not large enough to detect less common adverse events reliably; longer-term adverse events and durability of protection remain to be determined.
- The paper states that ethical and practical barriers prevent following placebo recipients for the planned 2 years once the vaccine is approved and recommended, and that the data do not address whether vaccination prevents asymptomatic infection or establish a correlate of protection.
- The paper states that it does not address prevention of Covid-19 in younger adolescents, children, or pregnant women; the text also makes evident that the main safety subset was 49% female, 83% White, 9% Black or African American, 28% Hispanic or Latinx, with a median age of 52 years, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 3 Not checked · 59 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The favorable safety profile observed during phase 1 testing of BNT162b24,8 was confirmed in the phase 2/3 portion of the trial.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Partly supportedcites [4] Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. DOI: 10.1056/NEJMoa2027906. PMC7583697 33053279 sourceExperimental — accuracy not yet measured
The Introduction reports safety data from the Phase 1 portion of the trial, and the Discussion says those data helped select BNT162b2 for Phase 2/3 evaluation. The Discussion describes Phase 2/3 safety assessment as ongoing; this paper does not report Phase 2/3 results confirming the Phase 1 safety profile. No page numbers are available in our copy. (LLM, conf=0.90)
- Partly supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. sourceExperimental — accuracy not yet measured
The Safety and tolerability section reports no related serious adverse events, grade-4 reactions, or withdrawals due to related adverse events in this phase-I/II study, supporting the description of a favorable early safety profile. The paper does not report phase-2/3 safety results confirming that profile; its Clinical trial design section identifies the presented data as coming from a phase-I/II trial. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the reactogenicity profile of BNT162b2 represented mainly short-term local (i.e., injection site) and systemic responses.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Abstract > Conclusions
What the sources say
- Supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. source
The Safety and tolerability section reports local reactions, predominantly injection-site pain, and systemic reactions including fatigue and headache. It says reactions began within 24 hours and mostly resolved within two or three days, supporting the description of mainly short-term responses. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Severe fatigue was observed in approximately 4% of BNT162b2 recipients, which is higher than that observed in recipients of some vaccines recommended for older adults.12”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Could not verifycites [12] Cowling BJ, Perera RAPM, Valkenburg SA, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin Infect Dis 2020; 71: 1704- 1714. 31828291 PMC7289658 sourceExperimental — accuracy not yet measured
The Results section reports local reactions and serious adverse events after influenza vaccination, but gives no rate of severe fatigue. Searches for severe fatigue and systemic reactions found no passage in our copy that supports the comparison with BNT162b2 recipients. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cumulative incidence of Covid-19 cases over time among placebo and vaccine recipients begins to diverge by 12 days after the first dose, 7 days after the estimated median viral incubation period of 5 days,10 indicating the early onset of a partially protective effect of immunization.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Supportedcites [10] Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577- 582. 32150748 PMC7081172 source
The Discussion reports a median incubation period of 5.2 days, supporting the approximately five-day estimate to which the citation is attached. The vaccine–placebo divergence is not attributed to this source. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No deaths were considered by the investigators to be related to the vaccine or placebo.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Adverse Events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 69 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [46]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“However, both the Oxford-AstraZeneca and Pfizer vaccines give substantial initial efficacy after a single dose of vaccine against parental strains (∼76 and 89%, respectively)”
From Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) · cites this paper as Polack et al., 2020
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Most large Covid-19 vaccine efficacy trials have reported notably increased vaccine efficacy against severe versus mild to moderate disease.4–7”
From Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
84 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“although fatigue and headache were also reported by many placebo recipients”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“23% and 24%, respectively, after the second dose, among younger vaccine recipients; 17% and 14% among older recipients”
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citationProspects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Cowling, B. J., Perera, R. A. P. M., Valkenburg, S. A., Leung, N. H. L., Iuliano, A. D., Tam, Y. H., Wong, J. H. F., Fang, V. J., Li, A. P. Y., So, H. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1034 · Cited by 110
Cited by
Items 1,401–1,500 of 15,747
Improved control of SARS-CoV-2 by treatment with a nucleocapsid-specific monoclonal antibody
Dangi, T., Sanchez, S., Class, J., Richner, M., Visvabharathy, L., Chung, Y. R., Bentley, K., Stanton, R. J., Koralnik, I. J., Richner, J. M., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci162282 · Cited by 80
“Although vaccines and monoclonal antibody therapies can prevent severe disease and death, breakthrough infections can occur, highlighting the need for improving current vaccines and available treatments (1-9).”
Maeda, K., Amano, M., Uemura, Y., Tsuchiya, K., Matsushima, T., Noda, K., Shimizu, Y., Fujiwara, A., Takamatsu, Y., Ichikawa, Y., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-01930-y · Cited by 79
Pino, M., Abid, T., Ribeiro, S. P., Edara, V. V., Floyd, K. A., Smith, J. C., Latif, M. B., Sánchez, G. P., Dutta, D., Wang, S., et al. (2021) · Science Immunology · doi:10.1126/sciimmunol.abh3634 · Cited by 80
Tracking the COVID-19 vaccines: The global landscape
Yadav, T., Kumar, S., Mishra, G., & Saxena, S. K. (2023) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2023.2191577 · Cited by 97
“Polack et al.(23) have investigated the safe use and effectiveness of the BNT162b2 vaccine.”
BackgroundNiessl, J., Sekine, T., & Buggert, M. (2021) · Seminars in Immunology · doi:10.1016/j.smim.2021.101505 · Cited by 83
Chemaitelly, H., Ayoub, H. H., AlMukdad, S., Coyle, P., Tang, P., Yassine, H. M., Al-Khatib, H. A., Smatti, M. K., Hasan, M. R., Al-Kanaani, Z., et al. (2022) · The Lancet Microbe · doi:10.1016/s2666-5247(22)00287-7 · Cited by 76
Vaccine Enthusiasm and Hesitancy in Cancer Patients and the Impact of a Webinar
Kelkar, A. H., Blake, J. A., Cherabuddi, K., Cornett, H., McKee, B. L., & Cogle, C. R. (2021) · Healthcare · doi:10.3390/healthcare9030351 · Cited by 79
Keratoplasty Rejection After the BNT162b2 messenger RNA Vaccine
Wasser, L. M., Roditi, E., Zadok, D., Berkovitz, L., & Weill, Y. (2021) · Cornea · doi:10.1097/ico.0000000000002761 · Cited by 75
Espi, M., Charmetant, X., Barba, T., Koppe, L., Pelletier, C. C., Kalbacher, E., Chalençon, E., Mathias, V., Ovize, A., Cart-Tanneur, E., et al. (2021) · Kidney International · doi:10.1016/j.kint.2021.07.005 · Cited by 73
“8 Cause of renal failure NA Vascular 19 (18) Diabetes mellitus 37 (35) Glomerulonephritis 15 (14) Hereditary 3 (3) Uropathy 0 (0) Others 32 (30) Comorbidities Cardiovascular disease 46 (43) 1 (3) Respiratory disease 13 (12) 1 (3) Liver disease 5 (5) 0 (0) Diabetes mellitus 47 (44) 0 (0) History of COVID-19 14 (13) 4 (…”
Delayed Antibody and T-Cell Response to BNT162b2 Vaccination in the Elderly, Germany
Schwarz, T., Tober‐Lau, P., Hillus, D., Helbig, E. T., Lippert, L. J., Thibeault, C., Koch, W., Landgraf, I., Michel, J., Bergfeld, L., et al. (2021) · Emerging infectious diseases · doi:10.3201/eid2708.211145 · Cited by 86
Evolution of Cancer Vaccines—Challenges, Achievements, and Future Directions
Tay, B. Q., Wright, Q., Ladwa, R., Perry, C., Leggatt, G., Simpson, F., Wells, J. W., Panizza, B. J., Frazer, I. H., & Cruz, J. L. G. (2021) · Vaccines · doi:10.3390/vaccines9050535 · Cited by 76
Kahn, R., Schrag, S. J., Verani, J. R., & Lipsitch, M. (2022) · American Journal of Epidemiology · doi:10.1093/aje/kwac015 · Cited by 76
Polinski, J. M., Weckstein, A. R., Batech, M., Kabelac, C. A., Kamath, T. V., Harvey, R. A., Jain, S., Rassen, J. A., Khan, N. S., & Schneeweiß, S. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.2959 · Cited by 79
Nouailles, G., Adler, J. M., Pennitz, P., Peidli, S., Alves, L. G. T., Baumgardt, M., Bushe, J., Voß, A., Langenhagen, A. K., Langner, C., et al. (2023) · Nature Microbiology · doi:10.1038/s41564-023-01352-8 · Cited by 84
Gagne, M., Corbett, K. S., Flynn, B. J., Foulds, K. E., Wagner, D. A., Andrew, S. F., Todd, J.-P. M., Honeycutt, C. C., McCormick, L., Nurmukhambetova, S. T., et al. (2022) · Cell · doi:10.1016/j.cell.2021.12.002 · Cited by 72
“These observations were consistent with previous findings showing that breakthrough infections with Alpha (B.1.1.7) were associated with lower BNT162b2-elicited binding and neutralizing antibody titers immediately prior to infection (Bergwerk et al., 2021).”
BackgroundInfluentialEffectiveness of a Third Dose of BNT162b2 mRNA Vaccine
Saciuk, Y., Kertes, J., Shamir Stein, N., & Ekka Zohar, A. (2022) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab556 · Cited by 74
Zadok, O. I. B., Shaul, A. A., Ben‐Avraham, B., Yaari, V., Zvi, H. B., Shostak, Y., Pertzov, B., Eliakim‐Raz, N., Abed, G., Abuhazira, M., et al. (2021) · European Journal of Heart Failure · doi:10.1002/ejhf.2199 · Cited by 77
Antibody Responses to Natural SARS-CoV-2 Infection or after COVID-19 Vaccination
Altawalah, H. (2021) · Vaccines · doi:10.3390/vaccines9080910 · Cited by 80
“Safety and efficacy data from the clinical trials of the BNT162b2 (Pfizer/BioNTech vaccine), a nucleoside-modified mRNA formulated in lipid nanoparticles that encodes the SARS-CoV-2 S stabilized in its prefusion conformation, showed 95% effectivity in preventing COVID-19 and an efficacy between 90% and 100%, with very…”
Miocarditis aguda tras administración de vacuna BNT162b2 contra la COVID-19
García, J. B., Ortega, P. P., Fernández, J. A. B., León, A. C., Burgos, L. R., & Dorta, E. C. (2021) · Revista Española de Cardiología · doi:10.1016/j.recesp.2021.03.009 · Cited by 78
Safety and efficacy of COVID-19 vaccines in multiple sclerosis patients
Kelly, H. M., Sokola, B. S., & Abboud, H. (2021) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2021.577599 · Cited by 79
Prahl, M. K., Golan, Y., Cassidy, A. G., Matsui, Y., Li, L., Alvarenga, B. D., Chen, H., Jigmeddagva, U., Lin, C. Y., Gonzalez, V. J., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32188-1 · Cited by 83
Dong, S., Feng, Z., Ma, R., Zhang, T., Jiang, J., Li, Y., Zhang, Y., Li, S., Liu, X., Liu, X., et al. (2023) · Nano Letters · doi:10.1021/acs.nanolett.2c04486 · Cited by 80
Sex and gender differences in COVID-19: More to be learned!
Ya’qoub, L., Elgendy, I. Y., & Pepine, C. J. (2021) · American Heart Journal Plus Cardiology Research and Practice · doi:10.1016/j.ahjo.2021.100011 · Cited by 88
Hirotsu, Y., Kobayashi, H., Kakizaki, Y., Saito, A., Tsutsui, T., Kawaguchi, M., Shimamura, S., Hata, K., Hanawa, S., Toyama, J., et al. (2023) · Med · doi:10.1016/j.medj.2023.08.001 · Cited by 82
The Present and Future of Yellow Fever Vaccines
Hansen, C. A., & Barrett, A. D. T. (2021) · Pharmaceuticals · doi:10.3390/ph14090891 · Cited by 81
“Recently, there have been many developments in stabilizing mRNA molecules for use in vaccines, and multiple COVID-19 vaccines utilize mRNA technology [115,116].”
BackgroundTransient Cardiac Injury in Adolescents Receiving the BNT162b2 mRNA COVID-19 Vaccine
Snapiri, O., Danziger, C. R., Shirman, N., Weissbach, A., Lowenthal, A., Ayalon, I., Adam, D., Yarden‐Bilavsky, H., & Bilavsky, E. (2021) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0000000000003235 · Cited by 74
Havla, J. B., Schultz, Y., Zimmermann, H., Hohlfeld, R., Danek, A., & Kümpfel, T. (2021) · Journal of Neurology · doi:10.1007/s00415-021-10648-w · Cited by 81
Viral Myocarditis—From Pathophysiology to Treatment
Schultheiss, H.-P., Baumeier, C., Aleshcheva, G., Bock, C.-T., & Escher, F. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10225240 · Cited by 75
Mortari, E. P., Russo, C., Vinci, M. R., Terreri, S., Salinas, A. F., Piccioni, L., Alteri, C., Colagrossi, L., Coltella, L., Ranno, S., et al. (2021) · Cells · doi:10.3390/cells10102541 · Cited by 79
Sha, H., Zhang, X., & Qi, D. (2021) · Sustainable Cities and Society · doi:10.1016/j.scs.2021.103256 · Cited by 81
Lipid Nanoparticles for Organ-Specific mRNA Therapeutic Delivery
Żak, M. M., & Zangi, L. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13101675 · Cited by 79
“The anti-SARS-Cov-2 modRNA vaccines are the most prominent example, with millions of doses already administered worldwide [14,15].”
BackgroundMethodResultInfluentialCOVID-19 Vaccine Boosters: The Good, the Bad, and the Ugly
Rzymski, P., Camargo, C. A., Fal, A., Flisiak, R., Gwenzi, W., Kelishadi, R., Leemans, A., Nieto, J. J., Ozen, A., Perc, M., et al. (2021) · Vaccines · doi:10.3390/vaccines9111299 · Cited by 86
Wynberg, E., Han, A. X., Boyd, A. C., van Willigen, H. D. G., Verveen, A., Lebbink, R., van der Straten, K., Kootstra, N. A., van Gils, M. J., Russell, C. A., et al. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.05.090 · Cited by 81
“Study participants who had not yet been vaccinated by 4 April 2021 were invited to receive two doses as part of our study, administered 28 days apart, of the BNT162b2 mRNA (Pfizer/BioNTech) vaccine [9], which were made available to RECoVERED by the Dutch Ministry of Health, Wellbeing and Sport (RIVM).”
MethodAli, H., Ngo, D., Aribi, A. M., Arslan, S., Dadwal, S., Marcucci, G., Nakamura, R., Forman, S. J., Chen, J., & Malki, M. M. A. (2021) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2021.07.008 · Cited by 74
“Both the Pfizer-BioNTech BNT162b2 and Moderna mRNA-1273 vaccines had greater than 90% efficacy with tolerable safety profiles [3-7].”
InfluentialThe safety profile of COVID-19 vaccinations in the United States
Singh, A., Khillan, R., Mishra, Y., & Khurana, S. S. (2021) · American Journal of Infection Control · doi:10.1016/j.ajic.2021.10.015 · Cited by 80
Martínez-Baz, I., Trobajo-Sanmartín, C., Miqueleiz, A., Guevara, M., Fernández-Huerta, M., Burgui, C., Casado, I., Portillo, M. E., Navascués, A., Ezpeleta, C., et al. (2021) · Eurosurveillance · doi:10.2807/1560-7917.es.2021.26.39.2100894 · Cited by 74
“COV2-S, Janssen-Cilag International NV, Beerse, Belgium) are adenovirus-based vector vaccines [1-4].”
Zhu, X., Gebo, K. A., Abraham, A. G., Habtehyimer, F., Patel, E. U., Laeyendecker, O. B., Gniadek, T. J., Fernández, R. E., Baker, O. R., Ram, M., et al. (2023) · The Lancet Microbe · doi:10.1016/s2666-5247(23)00171-4 · Cited by 82
Self-citationStage III Hypertension in Patients After mRNA-Based SARS-CoV-2 Vaccination
Meylan, S., Livio, F., Foerster, M., Genoud, P., Marguet, F., & Wuerzner, G. (2021) · Hypertension · doi:10.1161/hypertensionaha.121.17316 · Cited by 74
Demaret, J., Corroyer-Simovic, B., Alidjinou, E. K., Goffard, A., Trauet, J., Miczek, S., Vuotto, F., Dendooven, A., Huvent‐Grelle, D., Podvin, J., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.778679 · Cited by 83
Dalamaga, Μ., Christodoulatos, G. S., Karampela, Ι., Vallianou, N. G., & Apovian, C. M. (2021) · Current Obesity Reports · doi:10.1007/s13679-021-00436-y · Cited by 78
Tartof, S. Y., Slezak, J. M., Puzniak, L., Hong, V. X., Frankland, T. B., Ackerson, B. K., Xie, F., Takhar, H. S., Ogun, O. A., Simmons, S. R., et al. (2023) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(23)00306-5 · Cited by 80
Salo, J., Hägg, M., Kortelainen, M., Leino, T., Saxell, T., Siikanen, M., & Sääksvuori, L. (2022) · Nature Communications · doi:10.1038/s41467-022-28825-4 · Cited by 73
Breadth of SARS-CoV-2 neutralization and protection induced by a nanoparticle vaccine
Li, D., Martinez, D. R., Schäfer, A., Chen, H., Barr, M., Sutherland, L. L., Lee, E., Parks, R., Mielke, D., Edwards, W., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33985-4 · Cited by 74
Preparing for the Coronavirus Disease (COVID-19) Vaccination: Evidence, Plans, and Implications
Jung, J. (2021) · Journal of Korean Medical Science · doi:10.3346/jkms.2021.36.e59 · Cited by 75
SARS-CoV-2 variants and COVID-19 vaccines: Current challenges and future strategies
Gong, W., Parkkila, S., Wu, X., & Aspatwar, A. (2022) · International Reviews of Immunology · doi:10.1080/08830185.2022.2079642 · Cited by 82
“The results of BNT162b2 vaccine efficacy in participants 16 years of age or older showed 95% protection [59] and in 12–15 years old recipients 100% protection [67].”
BackgroundThe mRNA Vaccine Revolution: COVID-19 Has Launched the Future of Vaccinology
Ye, Z., Harmon, J., Ni, W., Li, Y., Wich, D., & Xu, Q. (2023) · ACS Nano · doi:10.1021/acsnano.2c12584 · Cited by 75
The BCG Vaccine for COVID-19: First Verdict and Future Directions
González-Pérez, M., Sánchez-Tarjuelo, R., Shor, B., Nistal‐Villán, E., & Ochando, J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.632478 · Cited by 90
The immune response to SARS-CoV-2 in people with HIV
Höft, M. A., Burgers, W. A., & Riou, C. (2023) · Cellular and Molecular Immunology · doi:10.1038/s41423-023-01087-w · Cited by 93
O’Brien, M. N., Costa, A. P., Cebrero, Y. M., Joseph, J., Sarode, A., Zang, N., Kim, L. J., Hofmann, K., Wang, S., Goyon, A., et al. (2023) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.3c00390 · Cited by 83
Spinelli, M. A., Glidden, D. V., Gennatas, E. D., Bielecki, M., Beyrer, C., Rutherford, G. W., Chambers, H. F. “., Goosby, E., & Gandhi, M. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30982-8 · Cited by 82
Associations of the BNT162b2 COVID-19 vaccine effectiveness with patient age and comorbiditiesPreprint
Yelin, I., Katz, R., Herzel, E., Berman-Zilberstein, T., Ben‐Tov, A., Kuint, J., Gazit, S., Patalon, T., Chodick, G., & Kishony, R. (2021) · medRxiv · doi:10.1101/2021.03.16.21253686 · Cited by 76
Spatiotemporal Adaptations of Macrophage and Dendritic Cell Development and Function
Roquilly, A., Mintern, J. D., & Villadangos, J. A. (2022) · Annual Review of Immunology · doi:10.1146/annurev-immunol-101320-031931 · Cited by 84
UVEITIS AFTER THE BNT162b2 mRNA VACCINATION AGAINST SARS-CoV-2 INFECTION: A Possible Association
Rabinovitch, T., Ben‐Arie‐Weintrob, Y., Hareuveni‐Blum, T., Shaer, B., Vishnevskia‐Dai, V., Shulman, S., Newman, H., Biadsy, M., Masarwa, D., Fischer, N., et al. (2021) · Retina · doi:10.1097/iae.0000000000003277 · Cited by 120
“The patients were examined at hospital-based uveitis clinics across Israel, from January 2021 to May 2021.”
BackgroundInfluentialMaillard, A., Redjoul, R., Klémencie, M., Wallet, H. L., Bourgeois, A. L., D’Aveni, M., Huynh, A., Berceanu, A., Marchand, T., Chantepie, S., et al. (2021) · Blood · doi:10.1182/blood.2021014232 · Cited by 74
Evaluation of COVID-19 vaccine response in patients with cancer: An interim analysis
Tran, S., Truong, T. H., & Narendran, A. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.10.013 · Cited by 75
“Two mRNA-based vaccines, BNT162b2 produced by Pfizer-BioNTech (known as Comirnaty) and mRNA-1273 by Moderna (known as SpikeVax), have demonstrated significant effectiveness in enhancing immunogenicity against SARS-CoV-2 while maintaining an acceptable safety profile in the general population [37,38].”
A Research and Development (R&D) roadmap for influenza vaccines: Looking toward the future
Moore, K. A., Ostrowsky, J., Kraigsley, A. M., Mehr, A. J., Bresee, J., Friede, M., Gellin, B. G., Golding, J. P., Hart, P. J., Moen, A. C., et al. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.08.010 · Cited by 83
Inagaki, M., Abe, N., Li, Z., Nakashima, Y., Acharyya, S., Ogawa, K., Kawaguchi, D., Hiraoka, H., Banno, A., Meng, Z., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-38244-8 · Cited by 87
Origin and evolution of SARS-CoV-2
Pagani, I., Ghezzi, S., Alberti, S., Poli, G., & Vicenzi, E. (2023) · The European Physical Journal Plus · doi:10.1140/epjp/s13360-023-03719-6 · Cited by 96
Lipid Nanoparticles as Promising Carriers for mRNA Vaccines for Viral Lung Infections
Asr, M. H., Dayani, F., Segherloo, F. S., Kamedi, A., Neill, A. O., MacLoughlin, R. J., & Doroudian, M. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15041127 · Cited by 75
Single-dose BNT162b2 vaccine protects against asymptomatic SARS-CoV-2 infection
Jones, N. K., Rivett, L., Seaman, S., Samworth, R. J., Warne, B., Workman, C., Ferris, M., Wright, J., Quinnell, N., Shaw, A., et al. (2021) · eLife · doi:10.7554/elife.68808 · Cited by 73
Self-citationSadarangani, M., Soe, P., Shulha, H. P., Valiquette, L., Vanderkooi, O. G., Kellner, J. D., Muller, M. P., Top, K. A., Isenor, J. E., McGeer, A., et al. (2022) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(22)00426-1 · Cited by 79
Li, Z., Zhang, X., Ho, W., Li, F., Gao, M., Bai, X., & Xu, X. (2022) · ACS Nano · doi:10.1021/acsnano.2c07822 · Cited by 79
Wang, S., Mortazavi, J., Hart, J. E., Hankins, J. A., Katuska, L. M., Farland, L. V., Gaskins, A. J., Wang, Y., Tamimi, R. M., Terry, K. L., et al. (2022) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2022.07.003 · Cited by 86
Mucosal plasma cells are required to protect the upper airway and brain from infection
Wellford, S. A., Moseman, A. P., Dao, K., Wright, K., Chen, A. P., Plevin, J. E., Liao, T.-C., Mehta, N. U., & Moseman, E. A. (2022) · Immunity · doi:10.1016/j.immuni.2022.08.017 · Cited by 78
Unlocking the Therapeutic Applicability of LNP-mRNA: Chemistry, Formulation, and Clinical Strategies
Huang, X., Ma, Y., Ma, G., & Xia, Y. (2024) · Research · doi:10.34133/research.0370 · Cited by 96
“The development of messenger RNA (mRNA) vaccines by Pfizer-BioNTech and Moderna against the 2019 coronavirus disease (COVID-19) represented substantial strides in the evolution of mRNA therapy [1,2].”
SARS-CoV-2 elicits robust adaptive immune responses regardless of disease severity
Nielsen, S. S. F., Vibholm, L. K., Monrad, I., Olesen, R., Frattari, G. S., Pahus, M. H., Højen, J. F., Gunst, J. D., Erikstrup, C., Holleufer, A., et al. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103410 · Cited by 78
Reopell, L., Nolan, T. S., Gray, D. M., Williams, A., Brewer, L. C., Bryant, A. L., Wilson, G., Williams, E. C., Jones, C., McKoy, A., et al. (2023) · PLoS ONE · doi:10.1371/journal.pone.0281940 · Cited by 83
BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the Delta (B.1.617.2) variant in Qatar
(2021) · doi:10.1101/2021.08.11.21261885 · Cited by 450
Correlation of SARS-CoV-2 Breakthrough Infections to Time-from-vaccine; Preliminary Study
(2021) · doi:10.1101/2021.07.29.21261317 · Cited by 261
COVID-19 vaccination among pregnant people in the United States: a systematic review
Rawal, S., Tackett, R. L., Stone, R. H., & Young, H. N. (2022) · American Journal of Obstetrics & Gynecology MFM · doi:10.1016/j.ajogmf.2022.100616 · Cited by 85
“100616 safety and pregnancy outcomes compared with the general population.(9,10) The lack of safety and efficacy data means that pregnant people are left with 2 options: get the vaccine, with limited safety and efficacy data, or skip the vaccine, thus leaving themselves and their fetuses vulnerable to adverse effects…”
BackgroundA vaccine-induced public antibody protects against SARS-CoV-2 and emerging variants
Schmitz, A. J., Turner, J. S., Liu, Z., Zhou, J. Q., Aziati, I. D., Chen, R. E., Joshi, A., Bricker, T. L., Darling, T. L., Adelsberg, D. C., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.08.013 · Cited by 65
Hui, L., Marzan, M. B., Rolnik, D. L., Potenza, S., Pritchard, N., Said, J. M., Palmer, K. R., Whitehead, C. L., Sheehan, P. M., Ford, J., et al. (2022) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2022.10.040 · Cited by 80
Immunogenicity and efficacy of one and two doses of Ad26.COV2.S COVID vaccine in adult and aged NHP
Solforosi, L., Kuipers, H., Jongeneelen, M. A. C., Huber, S. K. R., van der Lubbe, J. E. M., Dekking, L., Czapska-Casey, D. N., Gil, A. I., Baert, M. R. M., Drijver, J., et al. (2021) · The Journal of Experimental Medicine · doi:10.1084/jem.20202756 · Cited by 74
Furer, V., Rondaan, C., Agmon‐Levin, N., van Assen, S., Bijl, M., Kapetanovic, M. C., de Thurah, A. L., Müeller-Ladner, U., Paran, D., Schreiber, K. I., et al. (2021) · RMD Open · doi:10.1136/rmdopen-2021-001594 · Cited by 78
Rethinking Remdesivir: Synthesis, Antiviral Activity, and Pharmacokinetics of Oral Lipid Prodrugs
Schooley, R. T., Carlin, A. F., Beadle, J. R., Valiaeva, N., Zhang, X., Clark, A. E., McMillan, R. E., Leibel, S. L., McVicar, R. N., Xie, J., et al. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01155-21 · Cited by 74
Krauson, A. J., Casimero, F. V. C., Siddiquee, Z., & Stone, J. R. (2023) · npj Vaccines · doi:10.1038/s41541-023-00742-7 · Cited by 85
A public vaccine-induced human antibody protects against SARS-CoV-2 and emerging variants
Schmitz, A. J., Turner, J. S., Liu, Z., Aziati, I. D., Chen, R. E., Joshi, A., Bricker, T. L., Darling, T. L., Adelsberg, D. C., Alsoussi, W. B., et al. (2021) · doi:10.1101/2021.03.24.436864 · Cited by 72
“Pfizer-BioNTech SARS-CoV-2 mRNA vaccine (BNT162b2) encodes the full-length prefusion stabilized SARS-3 CoV-2 S protein and induces robust serum binding and neutralizing antibody responses in humans ( 9 , 28 ).”
BackgroundMethodMorello, W., Vianello, F. A., Proverbio, E., Peruzzi, L., Pasini, A., & Montini, G. (2021) · Pediatric Nephrology · doi:10.1007/s00467-021-05330-2 · Cited by 77
Multifunctional role of exosomes in viral diseases: From transmission to diagnosis and therapy
Chaudhari, P., Ghate, V., Nampoothiri, M., & Lewis, S. (2022) · Cellular Signalling · doi:10.1016/j.cellsig.2022.110325 · Cited by 72
COVID-19 vaccination in pregnant and lactating women: a systematic review
Falsaperla, R., Leone, G., Familiari, M., & Ruggieri, M. (2021) · Expert Review of Vaccines · doi:10.1080/14760584.2021.1986390 · Cited by 79
Exclusion of pregnant and lactating women from COVID-19 vaccine trials: a missed opportunity
Spall, H. G. C. V. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab103 · Cited by 77
Anterior uveitis onset after bnt162b2 vaccination: is this just a coincidence?
Renisi, G., Lombardi, A., Stanzione, M., et al. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2021.07.035 · Cited by 72
Nanotechnologies for the delivery of biologicals: Historical perspective and current landscape
Durán‐Lobato, M., López-Estévez, A. M., Cordeiro, A. S., Dacoba, T. G., Crecente‐Campo, J., Torres, D., & Alonso, M. J. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113899 · Cited by 74
Acute myocarditis after a second dose of the mRNA COVID-19 vaccine: a report of two cases
Mansour, J., Short, R. G., Bhalla, S., Woodard, P. K., Verma, A., Robinson, X., & Raptis, D. A. (2021) · Clinical Imaging · doi:10.1016/j.clinimag.2021.06.019 · Cited by 73
SARS-CoV-2 spike S2-specific neutralizing antibodies
Li, C., & Chang, S. (2023) · Emerging Microbes & Infections · doi:10.1080/22221751.2023.2220582 · Cited by 73
Sanchez, A. J. D. S., Loughrey, D., Echeverri, E. S., Huayamares, S. G., Radmand, A., Paunovska, K., Hatit, M. Z. C., Tiegreen, K. E., Santangelo, P. J., & Dahlman, J. E. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202304033 · Cited by 90
A perspective on bleb and empty LNP structures
Simonsen, J. B. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.07.046 · Cited by 81
Parsonage Turner syndrome after COVID‐19 vaccination
Mahajan, S., Zhang, F., Mahajan, A., et al. (2021) · Muscle & Nerve · doi:10.1002/mus.27255 · Cited by 72
“navirus 2 (SARS-CoV-2) (coronavirus disease 2019 [COVID-19]) BNT162b2 (Pfizer, New York City, NY) vaccination have not reported significant neurological complications.(5) We describe a case report of PTS that developed a few days after administration of this vaccination.”
BackgroundEfficacy and Effectiveness of SARS-CoV-2 Vaccines: A Systematic Review and Meta-Analysis
Ghazy, R. M., Ashmawy, R., Hamdy, N. A., Elhadi, Y. A. M., Reyad, O. A., el Malawany, D. H., Almaghraby, A. M., Shaaban, R., & Taha, S. H. N. (2022) · Vaccines · doi:10.3390/vaccines10030350 · Cited by 82
“Polack, 2021 [42] USA RCT Sample size = (37,706) Inclusion: -Age ≥ 16 years, healthy or had stable chronic medical conditions -No medical history of COVID-19 -Did not receive immunosuppressive therapy -Had immunocompromising condition.”
BackgroundCOVID-19 vaccines: concerns beyond protective efficacy and safety
Lai, C., Chen, I., Chao, C., Lee, P., Ko, W., & Hsueh, P. (2021) · Expert Review of Vaccines · doi:10.1080/14760584.2021.1949293 · Cited by 72
Modeling the impact of SARS-CoV-2 variants and vaccines on the spread of COVID-19
Ramos, A. M., Pérez, M., Ferrández, M. R., Kubik, A. B., & Ivorra, B. (2021) · Communications in Nonlinear Science and Numerical Simulation · doi:10.1016/j.cnsns.2021.105937 · Cited by 77
“These values, given in [49] , must be taken with caution, since, as said in that work, their “study was not designed to assess the efficacy of a single-dose regimen”.”
Paunovska, K., Sanchez, A. J. D. S., Lokugamage, M. P., Loughrey, D., Echeverri, E. S., Cristian, A., Hatit, M. Z. C., Santangelo, P. J., Zhao, K., & Dahlman, J. E. (2022) · Nano Letters · doi:10.1021/acs.nanolett.2c03741 · Cited by 81
Nanotechnology‐Assisted RNA Delivery: From Nucleic Acid Therapeutics to COVID‐19 Vaccines
Rinoldi, C., Zargarian, S. S., Nakielski, P., Li, X., Liguori, A., Petronella, F., Presutti, D., Wang, Q., Costantini, M., Sio, L. D., et al. (2021) · Small Methods · doi:10.1002/smtd.202100402 · Cited by 86
Lei, J., Qi, S., Yu, X., Gao, X., Yang, K., Zhang, X., Cheng, M., Bai, B., Feng, Y., Lu, M., et al. (2024) · Angewandte Chemie International Edition · doi:10.1002/anie.202318515 · Cited by 77
Pfizer-BioNTech COVID-19 Vaccine (BNT162b2) Side Effects: A Systematic Review
Dighriri, I. M., Alhusayni, K. M., Mobarki, A. Y., Aljerary, I. S., Alqurashi, K. A., Aljuaid, F., Al-Amri, K. A., Mutwalli, A. A., Maashi, N. A., Aljohani, A., et al. (2022) · Cureus · doi:10.7759/cureus.23526 · Cited by 92
“When comparing the second and first doses of the vaccine, a study issued by the US Food and Drug Administration indicated that the incidence of local adverse effects was somewhat greater following the second dosage [44].”
BackgroundResultMinocha, P. K., Better, D. J., Singh, R. K., & Hoque, T. (2021) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2021.06.035 · Cited by 75
“The Pfizer-BioNTech coronavirus disease 2019 (COVID-19) messenger ribonucleic acid (mRNA) vaccine has an efficacy of 95% at preventing severe COVID-19, with a low reported incidence of serious adverse events during phase 2/3 global clinical trials.(1) On December 11, 2020, the US Food and Drug Administration (FDA) iss…”
BackgroundInfluentialCardiovascular Complications of SARS-CoV-2 Vaccines: An Overview
Shiravi, A. A., Ardekani, A., Sheikhbahaei, E., & Heshmat‐Ghahdarijani, K. (2021) · Cardiology and Therapy · doi:10.1007/s40119-021-00248-0 · Cited by 78
“A case of paroxysmal ventricular arrhythmia was reported in the Pfizer vaccine (BNT162b2) clinical trial, but no causal relationship was found [8].”
BackgroundReal-world effectiveness of BNT162b2 mRNA vaccine: a meta-analysis of large observational studies
Kow, C. S., & Hasan, S. (2021) · InflammoPharmacology · doi:10.1007/s10787-021-00839-2 · Cited by 62
Metadata
- Authors
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- From Fundacion INFANT (F.P.P.) and iTrials-Hospital Militar Central (G.P.M.), Buenos Aires; State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.) — both in New York; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., P.L.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and Centro Paulista de Investigação Clinica, São Paulo (C.Z.) — both in Brazil; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (ÖT., U.Ş.), and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Centre, Karl Bremer Hospital, Cape...
- Corresponding author
- Absalon, Judith
- ORCID
- Polack, Fernando P.
- Thomas, Stephen J.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Moreira, Edson D.
- Zerbini, Cristiano
- Swanson, Kena A.
- Roychoudhury, Satrajit
- Li, Ping
- Cooper, David
- Frenck, Robert W.
- Hammitt, Laura L.
- Türeci, Özlem
- Ünal, Serhat
- Mather, Susan
- Dormitzer, Philip R.
- Şahin, Uğur
- Jansen, Kathrin U.
- Gruber, William C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-31
- Volume
- 383
- Issue
- 27
- Pages
- 2603-2615
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7745181
- OpenAlex
- W3111255098
- Cited by
- 14,592
- References
- 8
- Citations by year
- 2026: 756 · 2025: 1216 · 2024: 1543 · 2023: 2310 · 2022: 4192 · 2021: 4494 · 2020: 77
- FWCI
- 362.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- BioNTech and Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, severe COVID-19 prevention, two-dose regimen, serious adverse events, subgroup analysis, immunogenicity, immunocompromised patients, pregnant and lactating women
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Fatigue, Female, Headache, Humans, Immunization, Secondary, Male, Middle Aged, Vaccines, Synthetic, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.